BioSpace News Archive

Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Brion W. Murray, Ph.D., as Senior Vice President of Research.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).

Synthekine Inc. today announced it has entered into a worldwide research collaboration and license agreement with Merck, known as MSD outside the United States and Canada.

Abiomed’s (NASDAQ:ABMD) Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2021 , the annual scientific symposium of the Cardiovascular Research Foundation.

Neurotech Pharmaceuticals announced today that Thomas Aaberg, Jr., M.D. has been appointed to the position of Chief Medical Officer (CMO).

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on October 29, 2021, the Company participated in a productive Type A Meeting with the US Food and Drug Administration (FDA).

UroGen Pharma Ltd. today announced that it will host a virtual “Spotlight Event” on Wednesday, November 10, 2021 at 11:00 a.m. Eastern Time.

HMNC Brain Health, a clinical-stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced the appointment of Dr. Katarina Jelic Maiboe as Head of Regulatory Affairs, effective November 1, 2021.

Mustang Bio, Inc. today announced that the company has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (“NIH”).

Thermo Fisher Scientific, the world leader in serving science, and MSAID, the leader in proteomics artificial intelligence, have collaborated to provide proteomics researchers with advanced mass spectrometry software that generates market-leading biological insight from acquired data by substantially increasing peptide identification and quantitation capabilities using artificial intelligence (AI) and deep learning.